Country: United States
Language: English
Source: NLM (National Library of Medicine)
ATORVASTATIN CALCIUM TRIHYDRATE (UNII: 48A5M73Z4Q) (ATORVASTATIN - UNII:A0JWA85V8F)
Mylan Pharmaceuticals Inc.
ATORVASTATIN CALCIUM TRIHYDRATE
ATORVASTATIN 10 mg
ORAL
PRESCRIPTION DRUG
Atorvastatin calcium tablets are indicated: Discontinue atorvastatin calcium tablets when pregnancy is recognized. Alternatively, consider the ongoing therapeutic needs of the individual patient. Atorvastatin calcium tablets decreases synthesis of cholesterol and possibly other biologically active substances derived from cholesterol; therefore, atorvastatin calcium tablets may cause fetal harm when administered to pregnant patients based on the mechanism of action [see Clinical Pharmacology (12.1) ]. In addition, treatment of hyperlipidemia is not generally necessary during pregnancy. Atherosclerosis is a chronic process and the discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hyperlipidemia for most patients. Available data from case series and prospective and retrospective observational cohort studies over decades of use with statins in pregnant women have not identified a drug-associated risk of major congenital malformation
Atorvastatin Calcium Tablets, USP are available containing atorvastatin calcium, USP equivalent to 10 mg, 20 mg, 40 mg or 80 mg of atorvastatin. The 10 mg tablets are white to off-white, film-coated, oval, unscored tablets debossed with 10 on one side of the tablet and blank on the other side. They are available as follows: NDC 0378-3950-77 bottles of 90 tablets NDC 0378-3950-05 bottles of 500 tablets The 20 mg tablets are white to off-white, film-coated, oval, unscored tablets debossed with 20 on one side of the tablet and blank on the other side. They are available as follows: NDC 0378-3951-77 bottles of 90 tablets NDC 0378-3951-05 bottles of 500 tablets The 40 mg tablets are white to off-white, film-coated, oval, unscored tablets debossed with 40 on one side of the tablet and blank on the other side. They are available as follows: NDC 0378-3952-77 bottles of 90 tablets NDC 0378-3952-05 bottles of 500 tablets The 80 mg tablets are white to off-white, film-coated, oval, unscored tablets debossed with 80 on one side of the tablet and blank on the other side. They are available as follows: NDC 0378-3953-77 bottles of 90 tablets NDC 0378-3953-05 bottles of 500 tablets Storage: Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.
Abbreviated New Drug Application
ATORVASTATIN CALCIUM- ATORVASTATIN CALCIUM TABLET, FILM COATED MYLAN PHARMACEUTICALS INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE ATORVASTATIN CALCIUM TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR ATORVASTATIN CALCIUM TABLETS. ATORVASTATIN CALCIUM TABLETS, FOR ORAL USE INITIAL U.S. APPROVAL: 1996 RECENT MAJOR CHANGES Contraindications, Pregnancy and Lactation (4) Removed 12/2022 Warnings and Precautions, CNS Toxicity (5.5) Removed 12/2022 INDICATIONS AND USAGE Atorvastatin calcium tablets are an HMG-CoA reductase inhibitor (statin) indicated (1): • • • • DOSAGE AND ADMINISTRATION • • • • • • DOSAGE FORMS AND STRENGTHS Tablets: 10 mg; 20 mg; 40 mg; 80 mg of atorvastatin (3). CONTRAINDICATIONS • To reduce the risk of: o o o Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD. MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD. Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD. As an adjunct to diet to reduce low-density lipoprotein (LDL-C) in: o o Adults with primary hyperlipidemia. Adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to other LDL-C-lowering therapies to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia. As an adjunct to diet for the treatment of adults with: o o Primary dysbetaliproteinemia. Hypertriglyceridemia. Take orally once daily with or without food (2.1). Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating atorvastatin calcium tablets, and adjust dosage if necessary (2.1). _Adults_ (2.2): o o Reco Read the complete document